Scotland · NHS Scotland MSAN
Medicine in short supply: Ongentys® (opicapone) 50mg For action
MSAN(2019)8 · Level 3 · issued 28 Oct 2019
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| are currently anticipated mid-January 2020, however exact dates are still to be confirmed. | Resupply date to be confirmed | — |
| by the specialist. The following alternative treatments are available: | Available | — |
| * Caution: increased risk of hepatotoxicity; discontinue if abnormal liver function tests or | Discontinued | — |
| symptoms of liver disorder; do not re-introduce tolcapone once discontinued. | Discontinued | — |
| impact) therapeutic class are available but which may likely to require a change in the class | Available | — |
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.